Xiaoping Ning

1.4k total citations · 1 hit paper
48 papers, 887 citations indexed

About

Xiaoping Ning is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Xiaoping Ning has authored 48 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Psychiatry and Mental health, 19 papers in Pathology and Forensic Medicine and 11 papers in Physiology. Recurrent topics in Xiaoping Ning's work include Migraine and Headache Studies (41 papers), Trigeminal Neuralgia and Treatments (18 papers) and Sympathectomy and Hyperhidrosis Treatments (9 papers). Xiaoping Ning is often cited by papers focused on Migraine and Headache Studies (41 papers), Trigeminal Neuralgia and Treatments (18 papers) and Sympathectomy and Hyperhidrosis Treatments (9 papers). Xiaoping Ning collaborates with scholars based in United States, Germany and Japan. Xiaoping Ning's co-authors include Joshua M. Cohen, Ronghua Yang, Lindsay Janka, Maja Galić, Messoud Ashina, Hans‐Christoph Diener, Michel D. Ferrari, Andrew H. Ahn, Matthias Müeller and Melissa Grozinski‐Wolff and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Neurology.

In The Last Decade

Xiaoping Ning

40 papers receiving 861 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

2019 274 citations Michel D. Ferrari, Hans‐Christoph Diener et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaoping Ning United States	12	823	469	239	83	83	48	887
Yngve Hallström United States	8	807 1.0×	492 1.0×	265 1.1×	137 1.7×	80 1.0×	11	964
Valentina Favoni Italy	16	559 0.7×	383 0.8×	189 0.8×	138 1.7×	51 0.6×	46	741
Carolyn Bernstein United States	11	590 0.7×	230 0.5×	174 0.7×	56 0.7×	64 0.8×	32	770
Alejandro Labastida‐Ramírez Netherlands	16	707 0.9×	359 0.8×	224 0.9×	160 1.9×	27 0.3×	30	893
Tricia Blankenbiller United States	4	893 1.1×	620 1.3×	367 1.5×	87 1.0×	23 0.3×	8	962
Ilenia Corbelli Italy	14	520 0.6×	250 0.5×	156 0.7×	116 1.4×	64 0.8×	30	691
Teshamae Monteith United States	14	792 1.0×	467 1.0×	246 1.0×	159 1.9×	95 1.1×	46	1.0k
Melissa Grozinski‐Wolff United States	5	1.2k 1.4×	808 1.7×	465 1.9×	116 1.4×	30 0.4×	7	1.2k
Barbara Schaeffler United States	10	790 1.0×	572 1.2×	335 1.4×	68 0.8×	21 0.3×	15	862

Countries citing papers authored by Xiaoping Ning

Since Specialization

Citations

This map shows the geographic impact of Xiaoping Ning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoping Ning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoping Ning more than expected).

Fields of papers citing papers by Xiaoping Ning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoping Ning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoping Ning. The network helps show where Xiaoping Ning may publish in the future.

Co-authorship network of co-authors of Xiaoping Ning

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoping Ning. A scholar is included among the top collaborators of Xiaoping Ning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoping Ning. Xiaoping Ning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hershey, Andrew D., et al.. (2026). Fremanezumab in Children and Adolescents with Episodic Migraine. New England Journal of Medicine. 394(3). 243–252.

Tatsumoto, Muneto, et al.. (2024). Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial. Headache The Journal of Head and Face Pain. 65(3). 399–406.

Lipton, Richard B., et al.. (2023). Efficacy of fremanezumab in reducing depression in patients with migraine and major depressive disorder: Results of the UNITE study. Journal of the Neurological Sciences. 455. 121661–121661. 1 indexed citations

Lipton, Richard B., et al.. (2023). Efficacy of fremanezumab treatment in reducing monthly migraine days in patients with migraine and major depressive disorder: Results from the UNITE study. Journal of the Neurological Sciences. 455. 121112–121112.

Saigoh, Kazumasa, Takao Takeshima, Masami Nakai, et al.. (2023). Fremanezumab for Chronic Migraine Prevention in Japanese Patients: Subgroup Analysis from Two International Trials. Journal of Pain Research. Volume 16. 1311–1319. 1 indexed citations

Imai, Noboru, Yuki Isogai, Yoshiyuki Shibasaki, et al.. (2023). Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Neurology and Therapy. 12(6). 1981–1991. 5 indexed citations

Takeshima, Takao, Masami Nakai, Yoshiyuki Shibasaki, et al.. (2022). Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients. The Journal of Headache and Pain. 23(1). 24–24. 9 indexed citations

MaassenVanDenBrink, Antoinette, Gisela M. Terwindt, Joshua M. Cohen, et al.. (2021). Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study. The Journal of Headache and Pain. 22(1). 152–152. 11 indexed citations

Gladstone, Jonathan P., Hans‐Christoph Diener, Xiaoping Ning, et al.. (2021). Efficacy in Patients Switching from Quarterly to Monthly Fremanezumab or Maintained on Monthly Fremanezumab Treatment Over 6 Months in the Phase 3b FOCUS Study (2124). Neurology. 96(15_supplement).

10.

Ashina, Messoud, Joshua M. Cohen, Maja Galić, et al.. (2021). Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. The Journal of Headache and Pain. 22(1). 68–68. 26 indexed citations

11.

Barash, Steve, et al.. (2021). Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. “Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials”. Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819–828. Epublished November 2020. Naunyn-Schmiedeberg s Archives of Pharmacology. 394(11). 2343–2346. 1 indexed citations

12.

Silberstein, Stephen D., et al.. (2020). Efficacy of Fremanezumab in Migraine Patients with Medication Overuse and Documented Inadequate Response to 2–4 Migraine Preventive Medication Classes: Subgroup Analysis of the Randomized, Placebo-controlled FOCUS Study (4240). Neurology. 94(15_supplement). 2 indexed citations

13.

Yeung, Paul, et al.. (2019). Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine With Concomitant Preventive Medication Use (P1.10-008). Neurology. 92(15_supplement). 1 indexed citations

14.

Lipton, Richard B., Joshua M. Cohen, Paul Yeung, et al.. (2019). Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine and Comorbid Moderate to Severe Depression (P1.10-024). Neurology. 92(15_supplement). 1 indexed citations

15.

Ning, Xiaoping, et al.. (2019). Fremanezumab Cardiovascular and Cerebrovascular Safety Profile: Pooled Data From Placebo-Controlled and Long-Term Studies (S17.005). Neurology. 92(15_supplement). 4 indexed citations

16.

Ferrari, Michel D., Hans‐Christoph Diener, Xiaoping Ning, et al.. (2019). Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. The Lancet. 394(10203). 1030–1040. 274 indexed citations breakdown →

17.

Kent, Justine, Stuart Kushner, Xiaoping Ning, et al.. (2012). Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study. Journal of Autism and Developmental Disorders. 43(8). 1773–1783. 87 indexed citations

18.

Ning, Xiaoping. (2011). The Protection Effects of Shenmai Injection on Sepsis Patient. 1 indexed citations

19.

Li, Huafang, Qing Rui, Xiaoping Ning, Haiyan Xu, & Niufan Gu. (2011). A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 35(4). 1002–1008. 84 indexed citations

20.

Ning, Xiaoping. (2002). Present Status and Conservation of Soils in Wenshan Nature Reserve. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact